Tier 3 — preclinical

Evaluation of high dose N-Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study

L Jayaram, P T King, J Hunt, M Lim, C Park, E Hu, L Dousha, P Ha, J B Bartlett, A M Southcott, S Muruganandan, S Vogrin, M A Rees, O M Dean, C A Wong
Pulm Pharmacol Ther 2024 84:102283

Bibliography

PubMed
PMID 38141851
DOI
10.1016/j.pupt.2023.102283
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignPilot clinical study
ModelHuman
Sample24 recruited; 17 completed
InterventionOral NAC 2,400 mg/day
Duration6 weeks
EndpointsLung function; Quality of life; Safety

What the study showed, in plain terms

Small pilot testing a higher oral NAC dose in bronchiectasis.

Key findings

Generated preliminary signals in selected pulmonary and quality-of-life measures.

What this study can and cannot tell us

Underpowered, high attrition relative to sample size and short duration; findings are exploratory.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology